Vinorelbine

Section: 8. Immunomodulators and antineoplastics
8.2. Antineoplastics and supportive medicines
8.2.1. Cytotoxic medicines

**Indication**
Other specified malignant neoplasms of bronchus or lung

**INN**
Vinorelbine

**Medicine type**
Chemical agent

**List type**
Complementary

**Additional notes**
For intravenous use only

**Formulations**
Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial

**EML status history**
First added in 2015 (TRS 994)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Vinorelbine

**DrugBank**
Vinorelbine

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, vinorelbine was added to the complementary list of the EML for use in treatment protocols for non-small cell lung cancer. The relevant extract from TRS994 regarding the Expert Committee’s 2015 consideration of treatment protocols for non-small cell lung cancer is attached.